217 related articles for article (PubMed ID: 9619059)
41. Solid papillary carcinoma of the breast: A special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment.
Guo S; Wang Y; Rohr J; Fan C; Li Q; Li X; Wang Z
Breast; 2016 Apr; 26():67-72. PubMed ID: 27017244
[TBL] [Abstract][Full Text] [Related]
42. Supradiaphragmatic manifestations of papillary serous adenocarcinoma of the ovary.
Patel SV; Spencer JA; Wilkinson N; Perren TJ
Clin Radiol; 1999 Nov; 54(11):748-54. PubMed ID: 10580766
[TBL] [Abstract][Full Text] [Related]
43. Ovarian carcinoma metastatic to the breast and axillary node.
Duda RB; August CZ; Schink JC
Surgery; 1991 Sep; 110(3):552-6. PubMed ID: 1887382
[TBL] [Abstract][Full Text] [Related]
44. Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin.
Kanner WA; Galgano MT; Stoler MH; Mills SE; Atkins KA
Int J Gynecol Pathol; 2008 Oct; 27(4):491-5. PubMed ID: 18753974
[TBL] [Abstract][Full Text] [Related]
45. [Metastasis of a papillary cystadenocarcinoma of the ovary in an axillary lymph node].
Treumann T; Hof N; Höss C; Kolben M; Nathrath W
Rofo; 1998 Mar; 168(3):302-4. PubMed ID: 9551122
[No Abstract] [Full Text] [Related]
46. Immunohistochemistry of a component protein of the breast cystic disease fluid with mol. wt 15,000.
Le Doussal V; Zangerle PF; Collette J; Spyratos F; Hacene K; Briere M; Franchimont P; Gest J
Eur J Cancer Clin Oncol; 1985 Jun; 21(6):715-25. PubMed ID: 3894034
[TBL] [Abstract][Full Text] [Related]
47. Progesterone binding cyst protein in hormone receptor positive breast cancer; a predictive factor for effect of adjuvant tamoxifen treatment.
Søreide JA; Kolnes J; Skarstein A; Aas T; Kvinnsland S
Anticancer Res; 1994; 14(5B):2105-8. PubMed ID: 7840507
[TBL] [Abstract][Full Text] [Related]
48. Clinical significance of neuroendocrine carcinoma of the breast.
Sapino A; Papotti M; Righi L; Cassoni P; Chiusa L; Bussolati G
Ann Oncol; 2001; 12 Suppl 2():S115-7. PubMed ID: 11762336
[TBL] [Abstract][Full Text] [Related]
49. [Serous papillary cancer of the peritoneum: a multicentric primary disease].
Maassen V; Debus-Thiede G
Zentralbl Gynakol; 1993; 115(8):347-54. PubMed ID: 8212940
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: a statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein.
Ormsby AH; Snow JL; Su WP; Goellner JR
J Am Acad Dermatol; 1995 May; 32(5 Pt 1):711-6. PubMed ID: 7722013
[TBL] [Abstract][Full Text] [Related]
51. E-cadherin immunohistochemical analysis of histiocytoid carcinoma of the breast.
Gupta D; Croitoru CM; Ayala AG; Sahin AA; Middleton LP
Ann Diagn Pathol; 2002 Jun; 6(3):141-7. PubMed ID: 12089723
[TBL] [Abstract][Full Text] [Related]
52. Ovarian carcinoma metastatic to the breast.
Wadhwa J; Dawar R; Kumar L
Clin Oncol (R Coll Radiol); 1999; 11(6):419-21. PubMed ID: 10663336
[TBL] [Abstract][Full Text] [Related]
53. [A case of 19th year pulmonary metastasis after radical mastectomy for breast cancer].
Dohba S; Kondoh M; Fujita H; Kinami S; Inoue T; Komura Y; Ii T; Takegawa S; Kiriyama M; Kojima Y; Kibe Y; Watanabe K
Kyobu Geka; 2000 Dec; 53(13):1129-32. PubMed ID: 11127561
[TBL] [Abstract][Full Text] [Related]
54. Ovarian carcinoma metastasis to the breast and imaging features with histopathologic correlation: a case report and review of the literature.
Balaji R; Ramachandran K; Anila KR
Clin Breast Cancer; 2009 Aug; 9(3):196-8. PubMed ID: 19661047
[TBL] [Abstract][Full Text] [Related]
55. Circulating antibodies against the breast tumor marker GCDFP-15/gp17 in mammary carcinoma patients and in patients carrying benign breast conditions.
Pasquinelli R; Barba P; Capasso I; D'Aiuto M; D'Aiuto G; Anzisi AM; De Berardinis P; Guardiola J
Int J Cancer; 1999 Dec; 84(6):568-72. PubMed ID: 10567900
[TBL] [Abstract][Full Text] [Related]
56. Chondrosarcomatous differentiation in metastatic deposit of serous papillary cystadenocarcinoma.
Domoto H; Mano Y; Kita T; Kikuchi Y; Sato K; Aida S; Tamai S
Pathol Int; 2000 Jun; 50(6):497-501. PubMed ID: 10886727
[TBL] [Abstract][Full Text] [Related]
57. Metastatic ovarian cancer spreading into mammary ducts mimicking an in situ component of primary breast cancer: a case report.
Maeshima Y; Osako T; Morizono H; Yunokawa M; Miyagi Y; Kikuchi M; Ueno T; Ohno S; Akiyama F
J Med Case Rep; 2021 Feb; 15(1):78. PubMed ID: 33593410
[TBL] [Abstract][Full Text] [Related]
58. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
59. Axillary lymphadenopathy as the primary presentation of primary peritoneal carcinoma.
Berker B; Ortac F; Ataoglu O
Gynecol Obstet Invest; 2002; 54(4):232-6. PubMed ID: 12592068
[TBL] [Abstract][Full Text] [Related]
60. Uterine papillary serous carcinoma presenting as distant lymph node metastasis.
Ng JS; Han AC; Edelson MI; Rosenblum NG
Gynecol Oncol; 2001 Mar; 80(3):417-20. PubMed ID: 11263944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
